Pier Francesco Ferrucci (Pier Francesso Ferrucci)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Topics

Liver Metastases

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Reinhard Dummer, Philippa Corrie, Ralf Gutzmer, Tarek M Meniawy, Michele Del Vecchio, Celeste Lebbè, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James M G Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, Michele Maio
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo Antonio Ascierto, Paul D Nathan, Piotr Lukasz Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandala, Paul C Lorigan, Pier Francesco Ferrucci, Jean-Jacques Grob, Nicolas Meyer, Helen J Gogas, Daniil Stroyakovskiy, Ana M Arance, Jan C Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (13) (2022)
Georgina V Long, Pier Francesco Ferrucci, Adnan Khattak, Tarek M Meniawy, Patrick Alexander Ott, Michael Chisamore, Thomas Trolle, Agon Hyseni, Erik Heegaard
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. Future oncology (London, England) (2022)
Jason A Chesney, Antoni Ribas, Georgina V Long, Joanne M Jeter, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer, Piotr Lukasz Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew M Haydon, John R Hyngstrom, Johannes V van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari M VanderWalde, Scott J Diede, James R Anderson, Sheryl Treichel, Edward L Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen J Gogas
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paolo Antonio Ascierto, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen J Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, Emilia Cocorocchio
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers 13 (6) (2021)
Pier Francesco Ferrucci, Emilia Cocorocchio, Guido Bonomo, Gianluca Maria Varano, Paolo Della Vigna, Franco Orsi
A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells 10 (1) (2021)
Harriet Johansson, Giuseppe Spadola, Giulio Tosti, Mario Mandalà, Alessandro M Minisini, Paola Queirolo, Valentina Aristarco, Federica Baldini, Emilia Cocorocchio, Elena Albertazzi, Leonardo Zichichi, Saverio Cinieri, Costantino Jemos, Giovanni Mazzarol, Patrizia Gnagnarella, Debora Macis, Ines Tedeschi, Emanuela Omodeo Salè, Luigia Stefania Stucci, Bernardo Bonanni, Alessandro Testori, Elisabetta Pennacchioli, Pier Francesco Ferrucci, Sara Gandini, null On Behalf Of The Italian Melanoma Intergroup Imi
Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial. Nutrients 13 (6) (2021)
Pier Francesco Ferrucci, Marko Lens, Emilia Cocorocchio
Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. Current oncology reports 23 (12) (2021)
Jedd D Wolchok, Vanna Chiarion Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Lukasz Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O Butler, Andrew Hill, Ivan Marquez-Rodas, John B A G Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S Carlino, Celeste Lebbè, Grant A McArthur, Paolo Antonio Ascierto, Gregory A Daniels, Georgina V Long, Tuba Bas, Corey Ritchings, James M G Larkin, Frank Stephen Hodi
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Pier Francesco Ferrucci, Emilia Cocorocchio
Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers 14 (1) (2021)
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J Diede, Elizabeth S Croydon, Antoni Ribas, Paolo Antonio Ascierto, null null
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for immunotherapy of cancer 8 (2) (2021)
Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, Michele Del Vecchio, Roberta Depenni, Francesca Consoli, Dimitrios Bafaloukos, Pier Francesco Ferrucci, Skaiste Tulyte, Ivana Krajsová, Paolo Antonio Ascierto, Rossana Gueli, Ana Arance, Helen J Gogas, Hiya Banerjee, Teddy Saliba, Egbert de Jong, Bart Neyns
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers 13 (10) (2021)
Ewa Aladowicz, Letizia Granieri, Federica Marocchi, Simona Punzi, Giuseppina Giardina, Pier Francesco Ferrucci, Giovanni Mazzarol, Maria Capra, Giuseppe Viale, Stefano Confalonieri, Sara Gandini, Fiorenza Lotti, Luisa Lanfrancone
ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma. Cancers 12 (11) (2020)
Emilia Cocorocchio, Laura Pala, Angelo Battaglia, Sara Gandini, Fedro Alessandro Peccatori, Pier Francesco Ferrucci
Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta oncologica (Stockholm, Sweden) 57 (8) (2018)